|
1
|
Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang
W, Di W and Qiu L: MicroRNA-7 inhibits tumor metastasis and
reverses epithelial-mesenchymal transition through AKT/ERK1/2
inactivation by targeting EGFR in epithelial ovarian cancer. PLoS
One. 9:e967182014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu T, Hou L and Huang Y: EZH2-specific
microRNA-98 inhibits human ovarian cancer stem cell proliferation
via regulating the pRb-E2F pathway. Tumour Biol. 35:7239–7247.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
James PA, Sawyer S, Boyle S, Young MA,
Kovalenko S, Doherty R, McKinley J, Alsop K, Beshay V, Harris M, et
al: Large genomic rearrangements in the familial breast and ovarian
cancer gene BRCA1 are associated with an increased frequency of
high risk features. Fam Cancer. 14:287–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koensgen D, Bruennert D, Ungureanu S,
Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M,
Goyal P, et al: Polymorphism of the IL-8 gene and the risk of
ovarian cancer. Cytokine. 71:334–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing BL, Li T, Tang ZH, Jiao L, Ge SM,
Qiang X and OuYang J: Cumulative methylation alternations of gene
promoters and protein markers for diagnosis of epithelial ovarian
cancer. Genet Mol Res. 14:4532–4540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu Q, Ding YY, Song LX and Xu JF:
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome
of combined irinotecan plus cisplatin treatment in recurrent
ovarian cancer. Genet Mol Res. 14:7241–7247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan H, Tong J, Lin X, Han Q and Huang H:
Effect of the WWOX gene on the regulation of the cell cycle and
apoptosis in human ovarian cancer stem cells. Mol Med Rep.
12:1783–1788. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao
YC, Xu LW, Yang XB, Geng LG, Dou QL and Jia RP: MicroRNA expression
profiles in muscle-invasive bladder cancer: Identification of a
four-microRNA signature associated with patient survival. Tumour
Biol. 36:8159–8166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M
and Enokida H: The microRNA expressions signature of bladder cancer
by deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D and Bieche I: microRNA expression profile in a
large series of bladder tumors: Identification of a 3-miRNA
signature associated with aggressiveness of muscle-invasive bladder
cancer. Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang AM, Ma K, Song Y, Wang B, Feng Y,
Liu L and Xia X: Genetic polymorphisms of the IFNλ genes are
associated with biochemical features in Han Chinese with HCV
infection from Yunnan Province, China. Infect Genet Evol.
21:161–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang AM, Ma K, Song Y, Feng Y, Duan H,
Zhao P, Wang B, Xu G, Li Z and Xia X: Mitochondrial DNAs decreased
and correlated with clinical features in HCV patients from Yunnan,
China. Mitochondrial DNA A DNA Mapp Seq Anal. 27:2516–2519.
2016.PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jabbari N, Reavis AN and McDonald JF:
Sequence variation among members of the miR-200 microRNA family is
correlated with variation in the ability to induce hallmarks of
mesenchymal-epithelial transition in ovarian cancer cells. J
Ovarian Res. 7:122014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maqbool R, Ismail R and Hussain M:
Mutations in MicroRNA genes and they binding sites are infrequently
associated with human colorectal cancer in the kashmiri population.
Microrna. 2:219–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De M, attos-Arruda L, Bottai G, Nuciforo
PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J,
Masci G, Corsi F, et al: MicroRNA-21 links
epithelial-to-mesenchymal transition and inflammatory signals to
confer resistance to neoadjuvant trastuzumab and chemotherapy in
HER2-positive breast cancer patients. Oncotarget. 6:37269–37280.
2015.PubMed/NCBI
|
|
17
|
Wang X, Li Y, Qi W, Zhang N, Sun M, Huo Q,
Cai C, Lv S and Yang Q: MicroRNA-99a inhibits tumor aggressive
phenotypes through regulating HOXA1 in breast cancer cells.
Oncotarget. 6:32737–32747. 2015.PubMed/NCBI
|
|
18
|
Sestini S, Boeri M, Marchiano A, Pelosi G,
Galeone C, Verri C, Suatoni P, Sverzellati N, La Vecchia C, Sozzi G
and Pastorino U: Circulating microRNA signature as liquid-biopsy to
monitor lung cancer in low-dose computed tomography screening.
Oncotarget. 6:32868–32877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui R, Kim T, Fassan M, Meng W, Sun HL,
Jeon YJ, Vicentini C, Tili E, Peng Y, Scarpa A, et al: MicroRNA-224
is implicated in lung cancer pathogenesis through targeting
caspase-3 and caspase-7. Oncotarget. 6:21802–21815. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang Y, Xu C and Fu Y: MicroRNA-17-5p
induces drug resistance and invasion of ovarian carcinoma cells by
targeting PTEN signaling. J Biol Res (Thessalon). 22:122015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niu K, Shen W, Zhang Y, Zhao Y and Lu Y:
MiR-205 promotes motility of ovarian cancer cells via targeting
ZEB1. Gene. 574:330–336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu T, Yuan J, Wang Y, Gong C, Xie Y and
Li H: MiR-661 contributed to cell proliferation of human ovarian
cancer cells by repressing INPP5J expressions. Biomed Pharmacother.
75:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ye Z, Zhao L, Li J, Chen W and Li X:
miR-30d blocked transforming growth factor β1-induced
epithelial-mesenchymal transition by targeting snail in ovarian
cancer cells. Int J Gynecol Cancer. 25:1574–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Ma L, Rao Q, Mao Y, Xin Y, Xu H, Li
C and Wang X: MiR-1271 inhibits ovarian cancer growth by targeting
cyclin G1. Med Sci Monit. 21:3152–3158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo T, Yu W, Lv S, Zhang C and Tian Y:
MiR-302a inhibits the tumorigenicity of ovarian cancer cells by
suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880.
2015.PubMed/NCBI
|
|
26
|
Mussnich P, Rosa R, Bianco R, Fusco A and
D'Angelo D: MiR-199a-5p and miR-375 affect colon cancer cell
sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther
Targets. 19:1017–1026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen
T, Chen Z, Huang S, Gu J, Li J, et al: MiR-199a-5p is negatively
associated with malignancies and regulates glycolysis and lactate
production by targeting hexokinase 2 in liver cancer. Hepatology.
62:1132–1144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim BK, Yoo HI, Kim I, Park J and Kim Yoon
S: FZD6 expression is negatively regulated by miR-199a-5p in human
colorectal cancer. BMB Rep. 48:360–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JM, Heo MJ, Lee CG, Yang YM and Kim
SG: Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer,
directly inhibits E2F3, sensitizing mesenchymal tumor cells to
anti-cancer agents. Oncotarget. 6:3918–3931. 2015.PubMed/NCBI
|
|
30
|
Zhao X, He L, Li T, Lu Y, Miao Y, Liang S,
Guo H, Bai M, Xie H, Luo G, et al: SRF expedites metastasis and
modulates the epithelial to mesenchymal transition by regulating
miR-199a-5p expression in human gastric cancer. Cell Death Differ.
21:1900–1913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu Y, Liu J, Jiang B, Chen J, Fu Z, Bai F,
Jiang J and Tang Z: MiR-199a-5p loss up-regulated DDR1 aggravated
colorectal cancer by activating epithelial-to-mesenchymal
transition related signaling. Dig Dis Sci. 59:2163–2172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He XJ, Ma YY, Yu S, Jiang XT, Lu YD, Tao
L, Wang HP, Hu ZM and Tao HQ: Up-regulated miR-199a-5p in gastric
cancer functions as an oncogene and targets klotho. BMC Cancer.
14:2182014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi H, Liang B, Jia J, Liang N, Xu H, Ju G,
Ma S and Liu X: Differential roles of miR-199a-5p in
radiation-induced autophagy in breast cancer cells. FEBS Lett.
587:436–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saito Y, Nakaoka T and Saito H:
microRNA-34a as a therapeutic agent against human cancer. J Clin
Med. 4:1951–1959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ono S, Lam S, Nagahara M and Hoon DS:
Circulating microRNA Biomarkers as liquid biopsy for cancer
patients: Pros and cons of current assays. J Clin Med. 4:1890–1907.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miyazaki T, Ikeda K, Sato W, Horie-Inoue
K, Okamoto K and Inoue S: MicroRNA library-based functional
screening identified androgen-sensitive miR-216a as a player in
bicalutamide resistance in prostate cancer. J Clin Med.
4:1853–1865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
An F, Olaru AV, Mezey E, Xie Q, Li L,
Piontek KB and Selaru FM: MicroRNA-224 induces G1/S checkpoint
release in liver cancer. J Clin Med. 4:1713–1728. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Horsham JL, Kalinowski FC, Epis MR, Ganda
C, Brown RA and Leedman PJ: Clinical potential of microRNA-7 in
cancer. J Clin Med. 4:1668–1687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kelly BD, Miller N, Sweeney KJ, Durkan GC,
Rogers E, Walsh K and Kerin MJ: A Circulating MicroRNA signature as
a biomarker for prostate cancer in a high risk group. J Clin Med.
4:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stiuso P, Potenza N, Lombardi A,
Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N,
Castiello F, Porto S, et al: MicroRNA-423-5p promotes autophagy in
cancer cells and is increased in serum from hepatocarcinoma
patients treated with sorafenib. Mol Ther Nucleic Acids.
4:e2332015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Slattery ML, Mullany LE, Sakoda LC,
Samowitz WS, Wolff RK, Stevens JR and Herrick JS: Expression of
Wnt-signaling pathway genes and their associations with miRNAs in
colorectal cancer. Oncotarget. 9:6075–6085. 2017.PubMed/NCBI
|
|
43
|
Nunez Lopez YO, Victoria B, Golusinski P,
Golusinski W and Masternak MM: Characteristic miRNA expression
signature and random forest survival analysis identify potential
cancer-driving miRNAs in a broad range of head and neck squamous
cell carcinoma subtypes. Rep Pract Oncol Radiother. 23:6–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Weiner-Gorzel K, Dempsey E, Milewska M,
McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A,
Sharpe D, et al: Overexpression of the microRNA miR-433 promotes
resistance to paclitaxel through the induction of cellular
senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou J, Liu R, Wang Y, Tang J, Tang S,
Chen X, Xia K, Xiong W, Xu D, Wang S, et al: miR-199a-5p regulates
the expression of metastasis-associated genes in B16F10 melanoma
cells. Int J Clin Exp Pathol. 7:7182–7190. 2014.PubMed/NCBI
|
|
47
|
Lin HS, Gong JN, Su R, Chen MT, Song L,
Shen C, Wang F, Ma YN, Zhao HL, Yu J, et al: miR-199a-5p inhibits
monocyte/macrophage differentiation by targeting the activin A type
1B receptor gene and finally reducing C/EBPα expression. J Leukoc
Biol. 96:1023–1035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Raimondi L, Amodio N, Di Martino MT,
Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S,
D'Aquila P, et al: Targeting of multiple myeloma-related
angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor
activity. Oncotarget. 5:3039–3054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu ZY, Lu L, Liang J, Guo XR, Zhang PH and
Luo SJ: Keloid microRNA expression analysis and the influence of
miR-199a-5p on the proliferation of keloid fibroblasts. Genet Mol
Res. 13:2727–2738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Oltulu YM, Coskunpinar E, Ozkan G, Aynaci
E, Yildiz P, Isbir T and Yaylim I: Investigation of NF-κB1 and
NF-κBIA gene polymorphism in non-small cell lung cancer. Biomed Res
Int. 2014:5303812014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Huang H, Ma L, Li J, Yu Y, Zhang D, Wei J,
Jin H, Xu D, Gao J and Huang C: NF-κB1 inhibits c-Myc protein
degradation through suppression of FBW7 expression. Oncotarget.
5:493–505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yu Y, Zhang D, Huang H, Li J, Zhang M, Wan
Y, Gao J and Huang C: NF-κB1 p50 promotes p53 protein translation
through miR-190 downregulation of PHLPP1. Oncogene. 33:996–1005.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ferrer-Marin F, Gutti R, Liu ZJ and
Sola-Visner M: MiR-9 contributes to the developmental differences
in CXCR-4 expression in human megakaryocytes. J Thromb Haemost.
12:282–285. 2014. View Article : Google Scholar
|
|
54
|
Chen P, Price C, Li Z, Li Y, Cao D, Wiley
A, He C, Gurbuxani S, Kunjamma RB, Huang H, et al: miR-9 is an
essential oncogenic microRNA specifically overexpressed in mixed
lineage leukemia-rearranged leukemia. Proc Natl Acad Sci USA.
110:11511–11516. 2013. View Article : Google Scholar : PubMed/NCBI
|
